Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B as First Line Monotherapy in Patients With Unresectable Hepatocellular Cancer

NCT00627042 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00627042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00627042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B as First Line Monotherapy in Patients With Unresectable Hepatocellular Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
May 31, 2011
Enrollment
42 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma